JP2014525752A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014525752A5 JP2014525752A5 JP2014525418A JP2014525418A JP2014525752A5 JP 2014525752 A5 JP2014525752 A5 JP 2014525752A5 JP 2014525418 A JP2014525418 A JP 2014525418A JP 2014525418 A JP2014525418 A JP 2014525418A JP 2014525752 A5 JP2014525752 A5 JP 2014525752A5
- Authority
- JP
- Japan
- Prior art keywords
- dab
- variable domain
- immunoglobulin variable
- single immunoglobulin
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108060003951 Immunoglobulin Proteins 0.000 claims description 62
- 102000018358 immunoglobulin Human genes 0.000 claims description 62
- 238000006467 substitution reaction Methods 0.000 claims description 31
- 235000001014 amino acid Nutrition 0.000 claims description 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 210000004899 c-terminal region Anatomy 0.000 claims description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 15
- 235000004279 alanine Nutrition 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 11
- 101000611441 Solanum lycopersicum Pathogenesis-related leaf protein 6 Proteins 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 102220274086 rs1379627026 Human genes 0.000 claims description 11
- 206010035664 Pneumonia Diseases 0.000 claims description 10
- 206010069351 acute lung injury Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 208000019693 Lung disease Diseases 0.000 claims description 9
- 230000037430 deletion Effects 0.000 claims description 9
- 238000012217 deletion Methods 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 7
- 208000023504 respiratory system disease Diseases 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 7
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 6
- 206010013975 Dyspnoeas Diseases 0.000 claims description 6
- 208000012871 acute dyspnea Diseases 0.000 claims description 6
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 206010006451 bronchitis Diseases 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 208000027866 inflammatory disease Diseases 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- 230000004927 fusion Effects 0.000 claims description 5
- 235000018102 proteins Nutrition 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
- 206010014561 Emphysema Diseases 0.000 claims description 4
- 206010014950 Eosinophilia Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 4
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 4
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 208000007451 chronic bronchitis Diseases 0.000 claims description 4
- IEMCJUJOHAEFFW-UHFFFAOYSA-M potassium 2-[(2-acetyloxybenzoyl)amino]ethanesulfonate Chemical compound CC(=O)OC1=CC=CC=C1C(=O)NCCS(=O)(=O)[O-].[K+] IEMCJUJOHAEFFW-UHFFFAOYSA-M 0.000 claims description 4
- 102220041804 rs550499593 Human genes 0.000 claims description 4
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims description 4
- 108010047303 von Willebrand Factor Proteins 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 108020003175 receptors Proteins 0.000 claims description 3
- 102000005962 receptors Human genes 0.000 claims description 3
- 230000000241 respiratory effect Effects 0.000 claims description 3
- 102100036537 von Willebrand factor Human genes 0.000 claims description 3
- 229960001134 von willebrand factor Drugs 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 206010001881 Alveolar proteinosis Diseases 0.000 claims description 2
- 101150075175 Asgr1 gene Proteins 0.000 claims description 2
- 206010003487 Aspergilloma Diseases 0.000 claims description 2
- 201000002909 Aspergillosis Diseases 0.000 claims description 2
- 208000036641 Aspergillus infections Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 108010037897 DC-specific ICAM-3 grabbing nonintegrin Proteins 0.000 claims description 2
- 208000018071 Diaphragmatic disease Diseases 0.000 claims description 2
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 206010021133 Hypoventilation Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 102000003816 Interleukin-13 Human genes 0.000 claims description 2
- 108090000176 Interleukin-13 Proteins 0.000 claims description 2
- 108090000978 Interleukin-4 Proteins 0.000 claims description 2
- 102000004388 Interleukin-4 Human genes 0.000 claims description 2
- 108010002616 Interleukin-5 Proteins 0.000 claims description 2
- 102000000743 Interleukin-5 Human genes 0.000 claims description 2
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims description 2
- 206010025102 Lung infiltration Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000029001 Mediastinal disease Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010029443 Nocardia Infections Diseases 0.000 claims description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 2
- 208000002151 Pleural effusion Diseases 0.000 claims description 2
- 208000035109 Pneumococcal Infections Diseases 0.000 claims description 2
- 206010035667 Pneumonia anthrax Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims description 2
- 206010037423 Pulmonary oedema Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 2
- 208000017304 adult pulmonary Langerhans cell histiocytosis Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 230000007815 allergy Effects 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 201000009267 bronchiectasis Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 230000007613 environmental effect Effects 0.000 claims description 2
- 210000004602 germ cell Anatomy 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 230000009610 hypersensitivity Effects 0.000 claims description 2
- 208000000122 hyperventilation Diseases 0.000 claims description 2
- 230000000870 hyperventilation Effects 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 208000009449 inhalation anthrax Diseases 0.000 claims description 2
- 208000023372 inhalational anthrax Diseases 0.000 claims description 2
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 claims description 2
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 claims description 2
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000000414 obstructive effect Effects 0.000 claims description 2
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 claims description 2
- 206010035653 pneumoconiosis Diseases 0.000 claims description 2
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims description 2
- 208000005333 pulmonary edema Diseases 0.000 claims description 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims description 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 claims description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 claims description 2
- 210000003492 pulmonary vein Anatomy 0.000 claims description 2
- 208000021569 rheumatoid lung disease Diseases 0.000 claims description 2
- 201000002859 sleep apnea Diseases 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims description 2
- 101710153593 Albumin A Proteins 0.000 claims 1
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 201000007691 actinomycosis Diseases 0.000 claims 1
- 239000010425 asbestos Substances 0.000 claims 1
- 210000000621 bronchi Anatomy 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- -1 multimeric target Proteins 0.000 claims 1
- 208000024356 pleural disease Diseases 0.000 claims 1
- 229910052895 riebeckite Inorganic materials 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000033116 Asbestos intoxication Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 206010003441 asbestosis Diseases 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000004224 pleura Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161524488P | 2011-08-17 | 2011-08-17 | |
| US61/524,488 | 2011-08-17 | ||
| GBGB1121233.9A GB201121233D0 (en) | 2011-12-12 | 2011-12-12 | Modified proteins and peptides |
| GB1121226.3 | 2011-12-12 | ||
| GBGB1121226.3A GB201121226D0 (en) | 2011-12-12 | 2011-12-12 | Modified proteins and peptides |
| GB1121233.9 | 2011-12-12 | ||
| GB1121236.2 | 2011-12-12 | ||
| GBGB1121236.2A GB201121236D0 (en) | 2011-12-12 | 2011-12-12 | Proteins and peptides |
| PCT/EP2012/064632 WO2013014208A2 (en) | 2011-07-27 | 2012-07-25 | Antigen binding constructs |
| EPPCT/EP2012/064632 | 2012-07-25 | ||
| PCT/EP2012/065782 WO2013024059A2 (en) | 2011-08-17 | 2012-08-13 | Modified proteins and peptides |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018029267A Division JP2018117623A (ja) | 2011-08-17 | 2018-02-22 | 改変タンパク質およびペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014525752A JP2014525752A (ja) | 2014-10-02 |
| JP2014525752A5 true JP2014525752A5 (enExample) | 2015-10-01 |
| JP6297976B2 JP6297976B2 (ja) | 2018-03-20 |
Family
ID=47715521
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014525418A Active JP6297976B2 (ja) | 2011-08-17 | 2012-08-13 | 改変タンパク質およびペプチド |
| JP2018029267A Withdrawn JP2018117623A (ja) | 2011-08-17 | 2018-02-22 | 改変タンパク質およびペプチド |
| JP2019222041A Active JP6979446B2 (ja) | 2011-08-17 | 2019-12-09 | 改変タンパク質およびペプチド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018029267A Withdrawn JP2018117623A (ja) | 2011-08-17 | 2018-02-22 | 改変タンパク質およびペプチド |
| JP2019222041A Active JP6979446B2 (ja) | 2011-08-17 | 2019-12-09 | 改変タンパク質およびペプチド |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10808040B2 (enExample) |
| EP (3) | EP2744822B1 (enExample) |
| JP (3) | JP6297976B2 (enExample) |
| KR (2) | KR102143506B1 (enExample) |
| CN (2) | CN103917557B (enExample) |
| AR (1) | AR087521A1 (enExample) |
| AU (3) | AU2012296961B2 (enExample) |
| BR (1) | BR112014003679B1 (enExample) |
| CA (1) | CA2845029A1 (enExample) |
| CO (1) | CO7020851A2 (enExample) |
| DO (1) | DOP2014000029A (enExample) |
| EA (1) | EA027160B1 (enExample) |
| ES (1) | ES2813432T3 (enExample) |
| HK (1) | HK1214281A1 (enExample) |
| IL (1) | IL230918A0 (enExample) |
| MA (1) | MA35428B1 (enExample) |
| MX (1) | MX2014001883A (enExample) |
| MY (1) | MY167125A (enExample) |
| PE (1) | PE20141522A1 (enExample) |
| PH (1) | PH12014500380A1 (enExample) |
| SG (2) | SG10201605891TA (enExample) |
| TW (1) | TW201321405A (enExample) |
| UA (1) | UA118833C2 (enExample) |
| UY (1) | UY34254A (enExample) |
| WO (1) | WO2013024059A2 (enExample) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3434769B1 (en) | 2009-10-30 | 2020-11-25 | Novartis AG | Universal fibronectin type iii bottom-side binding domain libraries |
| EP2621953B1 (en) | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2944653A1 (en) * | 2011-06-23 | 2015-11-18 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| US9573992B2 (en) | 2011-06-23 | 2017-02-21 | Ablynx N.V. | Serum albumin binding proteins |
| EP4350345A3 (en) * | 2011-06-23 | 2024-07-24 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| CA2837998C (en) * | 2011-06-23 | 2022-03-01 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| ES2813432T3 (es) * | 2011-08-17 | 2021-03-23 | Glaxo Group Ltd | Proteínas y péptidos modificados |
| US9346884B2 (en) | 2011-09-30 | 2016-05-24 | Ablynx N.V. | Biological materials related to c-Met |
| US9328174B2 (en) | 2012-05-09 | 2016-05-03 | Novartis Ag | Chemokine receptor binding polypeptides |
| EP2895510A2 (en) * | 2012-09-13 | 2015-07-22 | Novartis AG | Single domain antibody with c-terminal modification |
| WO2014111550A1 (en) * | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| WO2015104322A1 (en) * | 2014-01-09 | 2015-07-16 | Glaxosmithkline Intellectual Property Development Limited | Treatment of inflammatory diseases with non-competitive tnfr1 antagonists |
| KR20250099289A (ko) | 2014-05-16 | 2025-07-01 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| US11009511B2 (en) | 2014-05-16 | 2021-05-18 | Ablynx N.V. | Methods for detecting and/or measuring anti-drug antibodies, in particular treatment-emergent anti-drug antibodies |
| KR20230145503A (ko) | 2014-05-16 | 2023-10-17 | 아블린쓰 엔.브이. | 개선된 면역글로불린 가변 도메인 |
| NL2013007B1 (en) | 2014-06-16 | 2016-07-05 | Ablynx Nv | Methods of treating TTP with immunoglobulin single variable domains and uses thereof. |
| CU20170041A7 (es) * | 2014-09-26 | 2017-09-06 | Macrogenics Inc | Diacuerpos monovalentes biespecíficos que son capaces de unir cd19 y cd3 |
| WO2016118733A1 (en) | 2015-01-21 | 2016-07-28 | Inhibrx Biopharma LLC | Non-immunogenic single domain antibodies |
| WO2016150845A1 (en) * | 2015-03-20 | 2016-09-29 | Ablynx Nv | Glycosylated immunoglobulin single variable domains |
| CN107427577A (zh) | 2015-03-31 | 2017-12-01 | 韦斯夸尔德有限公司 | 具有蛋白酶可切割接头的肽构建体 |
| WO2016156468A1 (en) | 2015-03-31 | 2016-10-06 | Vhsquared Limited | Polypeptides |
| ES2973042T3 (es) | 2015-03-31 | 2024-06-18 | Sorriso Pharmaceuticals Inc | Polipéptidos |
| CN107922491B (zh) | 2015-07-16 | 2021-09-28 | 印希比股份有限公司 | 多价和多特异性结合dr5的融合蛋白 |
| US12048753B2 (en) | 2015-10-01 | 2024-07-30 | Whitehead Institute For Biomedical Research | Labeling of antibodies |
| JP6920292B2 (ja) * | 2015-10-30 | 2021-08-18 | ジェネンテック， インコーポレイテッド | ヒンジが修飾された抗体断片及び作製方法 |
| BR112018008754A2 (pt) | 2015-10-30 | 2018-10-30 | Ablynx Nv | polipeptídeo contra il-23 |
| NO2768984T3 (enExample) | 2015-11-12 | 2018-06-09 | ||
| HK1258507A1 (zh) * | 2015-11-12 | 2019-11-15 | Ablynx Nv | 改进的p2x7受体结合剂和包含其的多肽 |
| SI3374392T1 (sl) | 2015-11-13 | 2022-04-29 | Ablynx Nv | Izboljšane variabilne domene imunoglobulina, ki vežejo serumski albumin |
| AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| MX2018006246A (es) * | 2015-11-18 | 2018-08-01 | Merck Sharp & Dohme | Aglutinantes ctla4p. |
| US10544222B2 (en) * | 2015-11-18 | 2020-01-28 | Merck Sharp & Dohme Corp. | PD1/CTLA4 binders |
| CA3004748C (en) | 2015-11-18 | 2021-11-16 | Merck Sharp & Dohme Corp. | Pd1 and/or lag3 binders |
| AU2016360987A1 (en) | 2015-11-27 | 2018-06-07 | Ablynx Nv | Polypeptides inhibiting CD40L |
| WO2017093478A1 (en) | 2015-12-04 | 2017-06-08 | Boehringer Ingelheim International Gmbh | Biparatopic polypeptides antagonizing wnt signaling in tumor cells |
| GB201522539D0 (en) | 2015-12-21 | 2016-02-03 | Hexcel Composites Ltd | Improvements in or relating to electrically conducting materials |
| CN109313183B (zh) * | 2016-06-23 | 2022-10-21 | 埃博灵克斯股份有限公司 | 免疫球蛋白单可变结构域的改进的药代动力学测定 |
| EP3519438A1 (en) | 2016-09-30 | 2019-08-07 | VHsquared Limited | Compositions |
| KR20230061582A (ko) | 2016-12-07 | 2023-05-08 | 아블린쓰 엔.브이. | 개선된 혈청 알부민 결합성 면역글로불린 단일 가변 도메인 |
| LT3571225T (lt) | 2017-01-17 | 2024-11-11 | Ablynx Nv | Patobulintos serumo albumino rišamosios medžiagos |
| RS66173B1 (sr) | 2017-01-17 | 2024-12-31 | Ablynx NV | Poboljšana veziva serumskog albumina |
| US12480957B2 (en) | 2017-03-31 | 2025-11-25 | Ablynx N.V. | Method of screening for anti-drug antibodies against immunoglobulin single variable domain-based drugs |
| BR112019022729A2 (pt) | 2017-05-31 | 2020-05-19 | Boehringer Ingelheim Int | polipeptídeos que antagonizam sinalização da wnt em células de tumor |
| KR20240170847A (ko) | 2017-09-08 | 2024-12-04 | 다케다 야쿠힌 고교 가부시키가이샤 | 제약된 조건적으로 활성화된 결합 단백질 |
| US11919949B2 (en) | 2017-09-27 | 2024-03-05 | Elasmogen Ltd | Specific binding molecules |
| MX2020008294A (es) * | 2018-02-06 | 2020-11-18 | Ablynx Nv | Metodos de tratamiento de episodio inicial de ttp con dominios variables simples de inmunoglobulina. |
| EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| TWI848953B (zh) | 2018-06-09 | 2024-07-21 | 德商百靈佳殷格翰國際股份有限公司 | 針對癌症治療之多特異性結合蛋白 |
| TWI838388B (zh) * | 2018-07-10 | 2024-04-11 | 美商雷傑納榮製藥公司 | 修飾結合分子以最小化已存在的交互作用 |
| CN109096394B (zh) * | 2018-09-21 | 2021-11-05 | 成都阿帕克生物科技有限公司 | 一种抗葡萄球菌蛋白a的b亚单位的纳米抗体及核酸分子和应用 |
| FR3088640A1 (fr) | 2018-10-14 | 2020-05-22 | Smart Diagnostix Pharma | Nouveau polypeptide se liant specifiquement a la proteine p16 |
| EP3873532A1 (en) | 2018-10-31 | 2021-09-08 | Novartis AG | Dc-sign antibody drug conjugates |
| GB201818460D0 (en) * | 2018-11-13 | 2018-12-26 | Crescendo Biologics Ltd | Single domain antibodies that bind human serum albumin |
| CN114390938B (zh) | 2019-03-05 | 2025-03-21 | 武田药品工业有限公司 | 受约束的条件性活化的结合蛋白 |
| EP3986571A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| EP3986931A1 (en) | 2019-06-21 | 2022-04-27 | Sorriso Pharmaceuticals, Inc. | Polypeptides |
| TWI878355B (zh) | 2019-10-02 | 2025-04-01 | 德商百靈佳殷格翰國際股份有限公司 | 用於癌症治療之多重專一性結合蛋白 |
| GB201914468D0 (en) | 2019-10-07 | 2019-11-20 | Crescendo Biologics Ltd | Binding Molecules |
| IL293780A (en) * | 2019-12-11 | 2022-08-01 | Cullinan Man Inc | Anti-serum albumin antibodies |
| WO2021119551A1 (en) * | 2019-12-11 | 2021-06-17 | Cullinan Oncology, Inc. | Anti-cd19 antibodies and multi-specific binding proteins |
| AR121706A1 (es) * | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
| AR123266A1 (es) | 2020-08-17 | 2022-11-16 | Maverick Therapeutics Inc | Proteínas de unión limitadas activadas de forma condicional |
| CN114075282B (zh) * | 2020-08-20 | 2024-01-02 | 南京融捷康生物科技有限公司 | Il-5的结合分子及其制备方法和应用 |
| IL300930A (en) * | 2020-08-27 | 2023-04-01 | Enosi Therapeutics Corp | Methods and compositions for the treatment of autoimmune diseases and cancer |
| WO2022051647A2 (en) | 2020-09-04 | 2022-03-10 | Maverick Therapeutics, Inc. | Constrained conditionally activated binding protein constructs with human serum albumin domains |
| TW202229335A (zh) * | 2020-10-12 | 2022-08-01 | 美商健生生物科技公司 | 用於多方向性生物輸送之生物合成材料及方法 |
| CN113307870B (zh) * | 2020-10-30 | 2022-12-23 | 上海洛启生物医药技术有限公司 | 抗il5纳米抗体及其应用 |
| US20250304686A1 (en) | 2020-12-14 | 2025-10-02 | Takeda Pharmaceutical Company Limited | Conditionally bispecific binding proteins |
| CN112341543B (zh) * | 2021-01-11 | 2021-04-23 | 广东赛尔生物科技有限公司 | 包含间充质干细胞外泌体的药物组合物在治疗疾病中的应用 |
| KR20230165798A (ko) | 2021-04-06 | 2023-12-05 | 다케다 야쿠힌 고교 가부시키가이샤 | 제약된 조건부 활성화 결합 단백질을 사용한 치료 방법 |
| CN118339179A (zh) | 2021-11-29 | 2024-07-12 | 江苏恒瑞医药股份有限公司 | 经修饰的蛋白或多肽 |
| US20250051826A1 (en) | 2021-12-13 | 2025-02-13 | Heraeus Medical Gmbh | Tests and methods for detecting bacterial infection |
| CN118946580A (zh) * | 2022-01-27 | 2024-11-12 | 詹森生物科技公司 | 增强的蛋白质组合物 |
| WO2023164551A1 (en) | 2022-02-23 | 2023-08-31 | Takeda Pharmaceutical Company Limited | Conditionally bispecific binding proteins |
| CN120077065A (zh) | 2022-07-27 | 2025-05-30 | 阿布林克斯有限公司 | 与新生儿Fc受体的特定表位结合的多肽 |
| EP4357778A1 (en) | 2022-10-20 | 2024-04-24 | Heraeus Medical GmbH | Treatment of microbial infections diagnosed using the biomarker d-lactate |
| CN115819599B (zh) * | 2022-11-29 | 2024-01-16 | 江苏耀海生物制药有限公司 | 一种利用重组大肠杆菌分泌表达纳米抗体Cablivi的方法 |
| WO2024151515A2 (en) | 2023-01-09 | 2024-07-18 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| TW202448926A (zh) | 2023-02-17 | 2024-12-16 | 比利時商艾伯霖克斯公司 | 結合新生兒fc受體之多肽 |
| CN121263437A (zh) | 2023-03-14 | 2026-01-02 | 奥德赛治疗股份有限公司 | 抗cd25抗原结合蛋白及其用途 |
| WO2024220763A1 (en) * | 2023-04-20 | 2024-10-24 | Xentria, Inc. | Methods for detecting an anti-drug antibody (ada) against an anti-tnf alpha antibody |
| TW202448951A (zh) | 2023-05-17 | 2024-12-16 | 美商奧迪希治療公司 | 經修飾之單域抗體 |
| WO2025006846A2 (en) | 2023-06-29 | 2025-01-02 | Odyssey Therapeutics, Inc. | Anti-trailr2 antigen-binding proteins and uses thereof |
| AR133188A1 (es) | 2023-07-05 | 2025-09-03 | Ablynx Nv | ANTAGONISTAS DE FcRn MEJORADOS PARA EL TRATAMIENTO DE ENFERMEDADES Y TRASTORNOS RELACIONADOS CON IgG |
| WO2025049750A1 (en) | 2023-08-30 | 2025-03-06 | Xilio Development, Inc. | Vhh masked cytokines and methods of use thereof |
| US20250101075A1 (en) | 2023-08-30 | 2025-03-27 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| AR133903A1 (es) | 2023-09-22 | 2025-11-12 | Ablynx Nv | Agentes de unión de albúmina bi- y multivalentes |
| WO2025080751A2 (en) | 2023-10-13 | 2025-04-17 | Odyssey Therapeutics, Inc. | Anti-cdh17 antigen-binding proteins and uses thereof |
| WO2025145329A1 (zh) * | 2024-01-03 | 2025-07-10 | 苏州智核生物医药科技有限公司 | 经修饰的免疫球蛋白单一可变结构域 |
| WO2025151752A1 (en) | 2024-01-10 | 2025-07-17 | Xilio Development, Inc. | Masked il-2 cytokines and methods of use thereof |
| WO2025167664A1 (zh) * | 2024-02-07 | 2025-08-14 | 原启生物科技(上海)有限责任公司 | Ror1抗原结合蛋白及其用途 |
| CN120025456B (zh) * | 2024-03-13 | 2025-11-07 | 寻济生物科技（北京）有限公司 | 一种抗vegfa融合构建体及其制备方法和应用 |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025255435A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Antigen-binding proteins against serum albumin and uses thereof |
| WO2025255558A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof |
| WO2026006708A2 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Anti-cd25 antigen-binding proteins and uses thereof |
| WO2026006809A1 (en) | 2024-06-27 | 2026-01-02 | Odyssey Therapeutics, Inc. | Multispecific molecules binding tnfr2 and cd25 and uses thereof |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69133476T2 (de) | 1990-08-29 | 2006-01-05 | GenPharm International, Inc., Palo Alto | Transgene Mäuse fähig zur Produktion heterologer Antikörper |
| ATE203767T1 (de) | 1992-08-21 | 2001-08-15 | Univ Bruxelles | Immunoglobuline ohne leichte ketten |
| FR2708622B1 (fr) | 1993-08-02 | 1997-04-18 | Raymond Hamers | Vecteur recombinant contenant une séquence d'un gène de lipoprotéine de structure pour l'expression de séquences de nucléotides. |
| IL127127A0 (en) * | 1998-11-18 | 1999-09-22 | Peptor Ltd | Small functional units of antibody heavy chain variable regions |
| WO2004003019A2 (en) | 2002-06-28 | 2004-01-08 | Domantis Limited | Immunoglobin single variant antigen-binding domains and dual-specific constructs |
| US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| US20060073141A1 (en) * | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
| CN1305905C (zh) | 2002-03-22 | 2007-03-21 | Aprogen株式会社 | 人源化抗体及其制备方法 |
| US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| GB0521621D0 (en) | 2005-10-24 | 2005-11-30 | Domantis Ltd | Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases |
| EP3415535B1 (en) * | 2005-05-20 | 2020-12-09 | Ablynx N.V. | Improved nanobodies tm for the treatment of aggregation-mediated disorders |
| DE102005023617A1 (de) * | 2005-05-21 | 2006-11-23 | Aspre Ag | Verfahren zum Mischen von Farben in einem Display |
| WO2006129843A2 (en) * | 2005-05-31 | 2006-12-07 | Canon Kabushiki Kaisha | Bispecific capturing molecule |
| JP2007008925A (ja) | 2005-05-31 | 2007-01-18 | Canon Inc | 標的物質捕捉分子 |
| US20100323905A1 (en) * | 2005-09-23 | 2010-12-23 | Academisch Ziekenhuis Leiden | Vhh for the Diagnosis, Prevention and Treatment of Diseases Associated with Protein Aggregates |
| JP2009519011A (ja) * | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | インターロイキン１受容体１型に結合する非競合ドメイン抗体フォーマット |
| US20080311111A1 (en) | 2005-12-01 | 2008-12-18 | Drew Philip D | Competitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1 |
| EP1976991A1 (en) | 2006-01-24 | 2008-10-08 | Domantis Limited | Fusion proteins that contain natural junctions |
| EP2057191A1 (en) | 2006-08-18 | 2009-05-13 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
| EP2121018A2 (en) * | 2006-12-13 | 2009-11-25 | Schering Corporation | Treating cancer with anti-igf1r antibody 19d12=sch 717454 |
| KR20100021601A (ko) | 2007-05-14 | 2010-02-25 | 바이오겐 아이덱 엠에이 인코포레이티드 | 단일-쇄 Ｆｃ(ＳｃＦｃ) 부분, 이를 포함하는 결합 폴리펩타이드, 및 이에 관련된 방법 |
| NZ580530A (en) | 2007-06-06 | 2012-04-27 | Domantis Ltd | Anti vegf polypeptides, antibody variable domains and antagonists |
| GB0724331D0 (en) * | 2007-12-13 | 2008-01-23 | Domantis Ltd | Compositions for pulmonary delivery |
| CA2688433A1 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Methods for selecting protease resistant polypeptides |
| CA2706425A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Method for obtaining polypeptide constructs comprising two or more single domain antibodies |
| WO2009068649A2 (en) | 2007-11-30 | 2009-06-04 | Glaxo Group Limited | Antigen-binding constructs |
| EP2220115A2 (en) | 2007-12-13 | 2010-08-25 | Glaxo Group Limited | Polypeptides, antibody variable domains & antagonists |
| AU2009227055A1 (en) | 2008-03-21 | 2009-09-24 | Ablynx Nv | Von Willebrand Factor specific binders and methods of use therefor |
| US8020937B2 (en) * | 2008-07-31 | 2011-09-20 | Lear Corporation | Layered technology for energy management of vehicle seating |
| US20110319597A1 (en) | 2008-08-14 | 2011-12-29 | Caphalon Australia Pty. Ltd. | Variant domain antibodies |
| BRPI0919979A2 (pt) | 2008-10-29 | 2015-12-15 | Wyeth Llc | formulações de moléculas de ligação de antígeno de domínio único |
| WO2010100135A1 (en) | 2009-03-05 | 2010-09-10 | Ablynx N.V. | Novel antigen binding dimer-complexes, methods of making/avoiding and uses thereof |
| SG174862A1 (en) * | 2009-04-10 | 2011-11-28 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorder |
| US9150640B2 (en) * | 2009-07-10 | 2015-10-06 | Ablynx N.V. | Method for the production of variable domains |
| GB201005063D0 (en) * | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| SG10201405259PA (en) * | 2009-12-18 | 2014-10-30 | Sanofi Sa | Novel antagonist antibodies and their fab fragments against gpvi and uses thereof |
| EP2621953B1 (en) * | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| EP2944653A1 (en) * | 2011-06-23 | 2015-11-18 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| CA2837998C (en) * | 2011-06-23 | 2022-03-01 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| ES2813432T3 (es) * | 2011-08-17 | 2021-03-23 | Glaxo Group Ltd | Proteínas y péptidos modificados |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
-
2012
- 2012-08-13 ES ES12746095T patent/ES2813432T3/es active Active
- 2012-08-13 UY UY0001034254A patent/UY34254A/es not_active Application Discontinuation
- 2012-08-13 KR KR1020197027997A patent/KR102143506B1/ko active Active
- 2012-08-13 EA EA201490262A patent/EA027160B1/ru not_active IP Right Cessation
- 2012-08-13 BR BR112014003679-9A patent/BR112014003679B1/pt active IP Right Grant
- 2012-08-13 UA UAA201401344A patent/UA118833C2/uk unknown
- 2012-08-13 WO PCT/EP2012/065782 patent/WO2013024059A2/en not_active Ceased
- 2012-08-13 EP EP12746095.4A patent/EP2744822B1/en active Active
- 2012-08-13 CN CN201280051150.4A patent/CN103917557B/zh active Active
- 2012-08-13 US US14/239,196 patent/US10808040B2/en active Active
- 2012-08-13 SG SG10201605891TA patent/SG10201605891TA/en unknown
- 2012-08-13 SG SG2014010482A patent/SG2014010482A/en unknown
- 2012-08-13 PH PH1/2014/500380A patent/PH12014500380A1/en unknown
- 2012-08-13 EP EP17191815.4A patent/EP3339322A3/en active Pending
- 2012-08-13 MY MYPI2014700336A patent/MY167125A/en unknown
- 2012-08-13 EP EP15180982.9A patent/EP2987806A3/en active Pending
- 2012-08-13 JP JP2014525418A patent/JP6297976B2/ja active Active
- 2012-08-13 CN CN201810128962.3A patent/CN108178800B/zh active Active
- 2012-08-13 CA CA2845029A patent/CA2845029A1/en active Pending
- 2012-08-13 AU AU2012296961A patent/AU2012296961B2/en not_active Ceased
- 2012-08-13 MX MX2014001883A patent/MX2014001883A/es unknown
- 2012-08-13 TW TW101129262A patent/TW201321405A/zh unknown
- 2012-08-13 PE PE2014000214A patent/PE20141522A1/es active IP Right Grant
- 2012-08-13 KR KR1020147006909A patent/KR102162413B1/ko active Active
- 2012-08-13 AR ARP120102955A patent/AR087521A1/es unknown
-
2014
- 2014-02-11 IL IL230918A patent/IL230918A0/en unknown
- 2014-02-12 CO CO14029997A patent/CO7020851A2/es unknown
- 2014-02-17 DO DO2014000029A patent/DOP2014000029A/es unknown
- 2014-03-06 MA MA36807A patent/MA35428B1/fr unknown
- 2014-06-26 HK HK16102229.1A patent/HK1214281A1/en unknown
-
2016
- 2016-12-22 AU AU2016277685A patent/AU2016277685B2/en not_active Ceased
-
2018
- 2018-02-22 JP JP2018029267A patent/JP2018117623A/ja not_active Withdrawn
-
2019
- 2019-03-05 AU AU2019201505A patent/AU2019201505A1/en not_active Abandoned
- 2019-12-09 JP JP2019222041A patent/JP6979446B2/ja active Active
-
2020
- 2020-09-08 US US17/014,441 patent/US20210017293A1/en not_active Abandoned
-
2024
- 2024-09-23 US US18/893,457 patent/US20250136721A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014525752A5 (enExample) | ||
| CN103917557B (zh) | 具有降低的与抗药物抗体结合的经修饰的单可变结构域抗体 | |
| US12428497B2 (en) | Multispecific antibody constructs | |
| AU2008334605B2 (en) | Polypeptides, antibody variable domains & antagonists | |
| CN106661128A (zh) | 构建氨基末端免疫球蛋白融合蛋白的方法及其组合物 | |
| US20150225479A1 (en) | Anti-IL-4/Anti-IL-13 Bispecific Antibody/Polyglutamate Formulations | |
| TW201125877A (en) | Stable anti-TNFR1 polypeptides, antibody variable domains & and antagonists | |
| KR20230010239A (ko) | 항-il-33 항체의 제형물 | |
| WO2023048650A1 (en) | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF | |
| JP2025504063A (ja) | 安定抗体製剤 | |
| US20250277042A1 (en) | TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Ra1 ANTIBODY OR BINDING FRAGMENT THEREOF | |
| EP4408466A1 (en) | Treatment of pruritis employing anti-il13ra1 antibody or binding fragment thereof | |
| NZ621203B2 (en) | Modified proteins and peptides |